Antengene (SEHK:6996) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

6996 주식 개요

바이오 제약 회사인 Antengene Corporation Limited는 중화권 및 국제적으로 새로운 종양 치료법을 개발하는 회사입니다.

6996 기본 분석
눈송이 점수
가치 평가	1/6
미래 성장	2/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

수익은 연간 61.52% 증가할 것으로 예상됩니다.

지난 5년 동안 수입이 매년 9.6% 증가했습니다.

위험 분석

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

의미 있는 시가총액이 없습니다. ( HK$567M )

Antengene Corporation Limited 경쟁사

Pak Fah Yeow International

SEHK:239

HK$779.1m

Hua Medicine (Shanghai)

SEHK:2552

HK$1.6b

Lansen Pharmaceutical Holdings

SEHK:503

HK$750.6m

Jilin Province Huinan Changlong Bio-pharmacy

SEHK:8049

HK$761.9m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Antengene
과거 주가
현재 주가	HK$0.82
52주 최고치	HK$2.25
52주 최저치	HK$0.77
베타	0.85
11개월 변경	-18.00%
3개월 변경 사항	-24.07%
1년 변경 사항	-46.41%
33년 변화	-95.75%
5년 변화	n/a
IPO 이후 변화	-95.51%

최근 뉴스 및 업데이트

Recent updates

Revenues Tell The Story For Antengene Corporation Limited (HKG:6996)

Jan 09

The Price Is Right For Antengene Corporation Limited (HKG:6996) Even After Diving 26%

Sep 20

Antengene Corporation Limited (HKG:6996) Analysts Just Slashed This Year's Estimates

Apr 03

What Type Of Shareholders Own The Most Number of Antengene Corporation Limited (HKG:6996) Shares?

Feb 22

주주 수익률

	6996	HK Pharmaceuticals	HK 마켓
7D	-12.8%	-2.9%	1.9%
1Y	-46.4%	-6.2%	2.1%

수익률 대 산업: 6996 지난 1년 동안 -3.4 %를 반환한 Hong Kong Pharmaceuticals 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: 6996 지난 1년 동안 2.1 %를 반환한 Hong Kong 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is 6996's price volatile compared to industry and market?
6996 volatility
6996 Average Weekly Movement	7.4%
Pharmaceuticals Industry Average Movement	5.6%
Market Average Movement	7.2%
10% most volatile stocks in HK Market	15.4%
10% least volatile stocks in HK Market	3.7%

안정적인 주가: 6996 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: 6996 의 주간 변동성( 7% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2017	201	Jay Mei	www.antengene.com

바이오 제약 회사인 안텐진 코퍼레이션은 중화권 및 국제적으로 새로운 종양 치료법을 개발하는 기업입니다. 회사의 상용화된 자산에는 중국 본토, 싱가포르, 호주, 홍콩, 마카오, 대만 성인 환자의 재발성/불응성 다발성 골수종(rrMM), 재발성/불응성 미만성 거대 B세포 림프종, 다발성 골수종(MM) 등 다양한 혈액암 및 고형 종양 치료를 위한 경구용 SINE 화합물인 ATG-010(셀린엑스소르)이 있습니다. 후기 단계 제품 후보로는 자궁경부암 및 기타 진행성 고형 종양 치료를 위한 mTOR 키나제 억제제인 ATG-008(오나타서팁)이 있습니다.

Antengene Corporation Limited 기본 사항 요약

Antengene 의 수익과 매출은 시가총액과 어떻게 비교하나요?
6996 기본 통계
시가총액	HK$553.41m
수익(TTM)	-HK$624.74m
수익(TTM)	HK$72.35m

7.6x

P/S 비율

-0.9x

P/E 비율

6996 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
6996 손익 계산서(TTM)
수익	CN¥67.31m
수익 비용	CN¥12.29m
총 이익	CN¥55.01m
기타 비용	CN¥636.20m
수익	-CN¥581.18m

최근 보고된 수익

Dec 31, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.86
총 마진	81.74%
순이익 마진	-863.51%
부채/자본 비율	15.7%

6996 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

6996 주식 개요

보상

위험 분석

Antengene Corporation Limited 경쟁사

SEHK:239

HK$779.1m

SEHK:2552

HK$1.6b

SEHK:503

HK$750.6m

SEHK:8049

HK$761.9m

가격 내역 및 성능

최근 뉴스 및 업데이트

Consensus revenue estimates decrease by 63%, EPS upgraded

Antengene Corporation Limited, Annual General Meeting, Jun 14, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study

Antengene Corporation Limited to Report Fiscal Year 2023 Results on Mar 22, 2024

Consensus revenue estimates decrease by 24%, EPS upgraded

Recent updates

Consensus revenue estimates decrease by 63%, EPS upgraded

Antengene Corporation Limited, Annual General Meeting, Jun 14, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study

Antengene Corporation Limited to Report Fiscal Year 2023 Results on Mar 22, 2024

Consensus revenue estimates decrease by 24%, EPS upgraded

Revenues Tell The Story For Antengene Corporation Limited (HKG:6996)

Antengene Corporation Limited Announces Successfully Included in 2023 National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance

Antengene Corporation Limited Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States

Antengene Announces Xpovio Regulatory Approval in Macau for the Treatment of Relapsed And/Or Refractory Multiple Myeloma

Antengene Corporation Limited Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day

Antengene Corporation Limited Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031

The Price Is Right For Antengene Corporation Limited (HKG:6996) Even After Diving 26%

New minor risk - Shareholder dilution

Consensus revenue estimates decrease by 16%, EPS upgraded

First half 2023 earnings released: CN¥0.36 loss per share (vs CN¥0.23 loss in 1H 2022)

Antengene Corporation Limited to Report First Half, 2023 Results on Aug 25, 2023

Antengene Corporation Limited Announces Xpovio Regulatory Approval in Hong Kong for the Treatment of Relapsed And/Or Refractory Multiple Myeloma

New minor risk - Share price stability

Antengene Announces Xpovio Plus Bortezomib and Dexamethasone Included for Reimbursement by the Pbs in Australia for the Treatment of Relapsed And/Or Refractory Multiple Myeloma

Antengene Corporation Limited Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers

Antengene Corporation Limited Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031

Antengene Corporation Limited (HKG:6996) Analysts Just Slashed This Year's Estimates

We're Not Very Worried About Antengene's (HKG:6996) Cash Burn Rate

Antengene Corporation Limited Announces Executive Changes

Antengene Corporation Limited Highlights Encouraging Atg-008 Efficacy Results from Torch-2 Study in Combination with Pd-1 Antibody in Relapsed/Metastatic Cervical Cancer

Less than half of directors are independent

Preliminary Results from Two Clinical Studies of Selinexor to Be Presented At 2022 Ash Annual Meeting

Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth

Antengene Corporation Limited Announces Approval for the Phase I Stamina-001 Study Toevaluate Atg-037

Antengene Corporation Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors

Antengene Corporation Limited Announces Approval in Taiwan for Atg-010 (Selinexor) for Thetreatment of Relapsed And/Or Refractory Multiplemyeloma and Diffuse Large B-Cell Lymphoma

First half 2022 earnings released: CN¥0.23 loss per share (vs CN¥0.37 loss in 1H 2021)

Antengene Corporation Limited Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

Antengene Corporation Limited to Report First Half, 2022 Results on Aug 30, 2022

We Think Antengene (HKG:6996) Can Afford To Drive Business Growth

Antengene Corporation Limited Announces First Patient Dosed in the Phase I STAMINA-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors

Antengene Corporation Limited Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule ATR Inhibitor ATG-018

Antengene Announces First Patient Dosed in the Phase I Stamina-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors

Antengene Corporation Limited Announces First Patient Dosed in the Phase I/II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas

Antengene Corporation Limited Announces That the Uses of XPOVIO®(Selinexor) for Multiple Myeloma Patients with First Relapse or Multiple Relapses Were Incorporated into the Guidelines for the Diagnosis and Management of Multiple Myeloma in China

Antengene Corporation Limited Announces Commercial Availability of Xpovio(R) (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China

Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China

Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress

Antengene Corporation Limited Announces Submission to the Human Research Ethics Committee in Australia for A Phase I Trial of ATG-018

Less than half of directors are independent

Antengene Corporation Limited Announces Pivotal "March" Study to Evaluate Selinexor (ATG-010) in Relapsed or Refractory Multiple Myeloma Published in BMC Medicine

Antengene Corporation Limited Announces Management Changes

Antengene Corporation Limited Announces the China National Medical Products Administration Approve A Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes

We're Hopeful That Antengene (HKG:6996) Will Use Its Cash Wisely

Antengene Announces Xpovio® Regulatory Approval in Singapore for the Treatment of Relapsed And/Or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications

Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037

Antengene Corporation Limited Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors

Antengene Corporation Limited announces First Patient Dose in Australia in ATG-101 First-in-Human Trial

National Medical Products Administration Grants Marketing Approval for Antengene Corporation Limited's Selinexor(Atg-010) in China

Antengene Presents Results of Phase 1b Touch Trial of Selinexor for the Treatment of T and NK-Cell Lymphoma At the 2021 American Society of Hematology (ASH) Annual Meeting

Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo® (nivolumab) in Advanced Solid Tumors

We're Hopeful That Antengene (HKG:6996) Will Use Its Cash Wisely

Antengene Corporation Limited Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in China